Australia is eagerly anticipating the arrival of retatrutide, a cutting-edge dual GIP and GLP-1 receptor agonist , representing a significant advance in obesity treatment . Early study data have demonstrated https://road-trip-mushroom-gummi784216.safiblog.com/90682/emerging-medication-in-australia-a-potential-breakthrough-for-obesity-management